Mycophenolate mofetil decreases antibody production after cardiac transplantation

J Heart Lung Transplant. 2002 Feb;21(2):282-5. doi: 10.1016/s1053-2498(01)00335-7.

Abstract

New immunosuppressive drugs are extensively being investigated for their effect on T-cell immunity, with far less being known about their effect on the humoral immune response. In view of the experimental and clinical evidence that humoral immunity contributes to acute and chronic rejection, we investigated post-transplant production of anti-vimentin and anti-HLA antibodies in 86 patients who were part of a worldwide clinical trial for mycophenolate mofetil in cardiac transplantation. The results demonstrate that patients taking MMF instead of azathioprine generated significantly fewer de novo anti-vimentin antibodies.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Antibody Formation / drug effects
  • Azathioprine / adverse effects
  • Azathioprine / immunology
  • Coronary Angiography
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / etiology
  • Disease Progression
  • Double-Blind Method
  • Graft Rejection / diagnosis
  • Graft Rejection / immunology
  • Heart Transplantation* / adverse effects
  • Heart Transplantation* / immunology*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / immunology
  • Mycophenolic Acid / adverse effects*
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / immunology
  • Postoperative Complications / diagnosis
  • Postoperative Complications / immunology
  • Time
  • Time Factors
  • Treatment Outcome
  • Vimentin / drug effects
  • Vimentin / immunology

Substances

  • Immunosuppressive Agents
  • Vimentin
  • Mycophenolic Acid
  • Azathioprine